Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).
Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Deputy Bureau Chief
